Rituximab for first episode of childhood nephrotic syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 and 18 years old.
- Your child has been diagnosed with steroid-sensitive nephrotic syndrome and is currently in remission.
- Your child's kidney function is normal (eGFR ≥ 90).
- Your child has not used immunosuppressive drugs (other than steroids for nephrotic syndrome) in the last 3 months.
- Your child has not had certain infections or vaccinations recently.
- You and your child (if 8 or older) agree to participate and sign consent forms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This trial tests a new medicine called zuberitamab for children who have just had their first episode of nephrotic syndrome and have responded well to steroids. The goal is to see if this medicine can help keep the disease from coming back, with fewer side effects than standard treatments.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests a drug called blinatumomab for children with a kidney condition that doesn't respond to standard treatments. It aims to see if it can help when other drugs have failed or caused side effects.
This trial tests a new medicine called ripertamab for children and young adults with nephrotic syndrome that keeps coming back or requires steroids. The goal is to see if it helps prevent relapses with fewer side effects.
Hear when a new Steroid-Sensitive Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.